Baxter International (NYSE:BAX) Stock Price Target Raised at Wells Fargo & Company

Baxter International (NYSE:BAX) had its price objective increased by Wells Fargo & Company from $23.00 to $25.00 in a report issued on Friday morning,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Several other equities research analysts also recently commented on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $25.00 price objective on shares of Baxter International in a research note on Thursday. The Goldman Sachs Group upped their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. UBS Group lifted their price target on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Wolfe Research started coverage on Baxter International in a research report on Tuesday, October 20th. They set a “peer perform” rating for the company. Finally, Citigroup dropped their price target on Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a research note on Monday, October 5th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Baxter International has an average rating of “Reduce” and a consensus target price of $23.00.

Baxter International Stock Performance

Shares of Baxter International stock opened at $22.95 on Friday. The firm has a market capitalization of $11.87 billion, a P/E ratio of -16.28, a PEG ratio of 3.54 and a beta of 0.65. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. The company has a 50 day moving average price of $24.59 and a 200 day moving average price of $21.37. Baxter International has a 52 week low of $15.73 and a 52 week high of $30.00.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. Baxter International had a negative net margin of 6.23% and a positive return on equity of 16.48%. Baxter International’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.69 EPS. Sell-side analysts expect that Baxter International will post 2.05 EPS for the current year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, November 27th will be paid a $0.01 dividend. The ex-dividend date is Friday, November 27th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is presently -1.93%.

Institutional Investors Weigh In On Baxter International

Several hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp acquired a new position in Baxter International in the second quarter valued at approximately $26,000. CYBER HORNET ETFs LLC grew its stake in shares of Baxter International by 52.4% during the 2nd quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 740 shares during the period. Community Bank N.A. acquired a new stake in shares of Baxter International during the 2nd quarter worth approximately $46,000. Versant Capital Management Inc grew its stake in shares of Baxter International by 552.2% during the 2nd quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares during the period. Finally, Wedbush Securities Inc. purchased a new position in shares of Baxter International during the 3rd quarter valued at approximately $605,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share, exceeding the $0.52 analyst consensus, while revenue increased 5% year over year to $2.98 billion and topped expectations of $2.91 billion. Growth was described as broad-based across the company’s segments. Baxter Q3 Earnings Beat on Broad-Based Growth, 2026 Outlook Raised
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, signaling confidence in operating performance despite ongoing pressure on profitability. However, quarterly EPS remained below the $0.69 reported a year earlier. Baxter Raises 2026 Earnings Guidance
• Positive Sentiment: Wells Fargo raised its price target for BAX to $25 from $23, implying potential upside from recent trading levels. The firm maintained an “equal weight” rating, suggesting a constructive but cautious view. Wells Fargo Baxter Analyst Ratings
• Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, or $0.04 annualized. The approximately 0.2% yield provides minimal income support but maintains a cash-return program. Baxter Raises Guidance and Declares Dividend
• Negative Sentiment: The FDA issued Baxter a warning letter citing CGMP violations. The regulatory action could increase remediation costs, create operational disruptions, and raise concerns about compliance and product quality. Baxter Received FDA Warning Letter

About Baxter International

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.